---
schema_version: "secwatch.filing_event.v1"
accession: "0000078003-25-000159"
form_type: "8-K"
ticker: "PFE"
cik: "0000078003"
company_name: "PFIZER INC"
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:43:41.558148+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pfizer completes $7B acquisition of Metsera, including contingent milestones up to $20.65/sh

## Summary
- Enterprise value ~$7.0B; each Metsera share converted into $65.60 cash at closing.
- Plus up to $20.65/sh in contingent value rights tied to three FDA/clinical milestones.
- Milestones: Phase 3 start for MET-097i+MET-233i combo ($4.60/sh), FDA nod for monthly MET-097i ($6.40/sh), FDA nod for combo ($9.65/sh).
- Acquisition aimed at bolstering Pfizer's obesity pipeline with GLP-1 receptor antagonist + amylin analog.

## SEC filing metadata
- accession: 0000078003-25-000159
- form_type: 8-K
- ticker: PFE
- cik: 0000078003
- company_name: PFIZER INC
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/78003/000007800325000159/0000078003-25-000159-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/78003/000007800325000159/pfe-20251113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000078003-25-000159
- JSON: https://secwatch.observer/filing/0000078003-25-000159.json
- Plain text: https://secwatch.observer/filing/0000078003-25-000159.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.